A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Combination regimen
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06875310Not verified
Four separate status dimensions
- RegistryRecruiting in registry
- SiteNot verifiedUnknown, so no conclusion can be drawn.
- International accessUnknownUnknown, so no conclusion can be drawn.
- Patient matchNot assessedUnknown, so no conclusion can be drawn.
Three statuses often treated as one
A recruiting registry status does not mean a patient can immediately join this study. These three questions are answered by different parties.
Registry status
Stated by the study record owner: whether the study is listed as recruiting. It does not state whether a site is active.
Site status
Stated by the facility: whether the site is running this study now. TanyaKanker has not verified this.
International access
Stated by facility policy: whether patients from outside the local country can be accepted.
Why this appears
Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify
- • Acceptance of patients from outside the local country has not been verified.
- • We have not verified that the study site is actively running this study.
- • Eligibility is determined by the study team, not by registry data.
- • This record has never been directly verified by us.
Preliminary screening only shows overlap and data needs. Eligibility is determined by the study team.
Why this study may be relevant
- This study is recorded for Lung Cancer, the same cancer group you are exploring.
- The study requirements mention marker KRAS, so your molecular result is relevant to discuss.
- Recorded interventions: Adagrasib, Pembrolizumab, Carboplatin.
- The study is in Phase 3 according to registry data.
- Locations are recorded in United States, Argentina, Australia.
The relevance above is assembled from registry data, not from an eligibility judgement.
Study basis
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Sponsor
- Mirati Therapeutics Inc.
- Registry
- ClinicalTrials.gov NCT06875310
- Phase
- Phase 3
Cancer and markers
Recorded interventions
Study locations
- United States
University of Alabama at Birmingham
Birmingham
- United States
Highlands Oncology Group - Springdale
Springdale
- United States
Providence Medical Foundation
Fullerton
- United States
Local Institution - 0682
Loma Linda
- United States
Helios Clinical Research
Long Beach
Showing 5 of 349 locations recorded in the registry.
What we know
- Registry status: Recruiting.
- Phase 3 with sponsor Mirati Therapeutics Inc..
- 349 locations recorded in the registry.
- Registry data updated 2026-10-13.
What we do not know yet
- Whether the site accepts patients from outside the local country.
- Whether the site is actively running the study now.
- Which cost components are borne by participants.
- Which documents the sponsor requires.
Main eligibility factors from the registry
- Protocol sex: all
- Protocol minimum age: 18 Years
- Complete eligibility criteria appear only in the study protocol and must be assessed by the study team.
This summary is taken from registry data. Complete criteria live in the study protocol and must be assessed by the study team.
Documents that may be needed
- Disease history summary from the treating doctor
- Most recent pathology report
- Molecular marker report if available
- Most recent imaging results
- List of current medicines
This is a general frame, not the sponsor's official list.
Updates and sources
- Registry update
- 2026-10-13
- Retrieved by TanyaKanker
- 2026-10-16
- Last verified
- Never
- Contact status
- Not contacted
Data comes from the public ClinicalTrials.gov registry of the US National Library of Medicine. Registry facts are public data; interpretation about international patient access, cost, and site readiness does NOT come from the registry and is marked unverified.
https://clinicaltrials.gov/study/NCT06875310Treatment categories
Cost
NOT VERIFIED
Not verified. The public registry does not include cost details for international patients and does not state payment coverage.
This information is not a diagnosis or a medical recommendation. Decisions remain with your medical team.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Other studies in a similar group
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221 | Phase 1 / Phase 2
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
NCT07458347 | Phase 1
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071 | Phase 1 / Phase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782 | Phase 2
Check preliminary match for your case
This screening shows overlap between your summary and the study, plus data that still needs to be completed. Eligibility remains the study team's decision.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- Adagrasib
Drug
Reason: Uses this drug
- Cisplatin
Drug
Reason: Uses this drug
- Pembrolizumab
Drug
Reason: Uses this drug
- Pemetrexed
Drug
Reason: Uses this drug
To check
- Clinical trial document checklist
Tool
Reason: Check documents before contacting the study team
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.